Review on Hypothetical Implementing TGF-β Family Members in Glaucoma Therapy

Ivan Sosa, MD1; Kata Culina, MD2; Alan Bosnar, MD, PhD3

1Department of Forensic Medicine and Criminalistics; Rijeka University School of Medicine; Rijeka; Croatia 2Ophthalmologist at “Okulisticki Centar”; Zagreb; Croatia

ABSTRACT

For quite some time, glaucoma has been regarded as more than just intraocular pressure [IOP] elevation. Significant contribution to this conceptual improvement has risen from a better understanding of ocular blood flow, vessel wall integrity and certain advanced ideas in neuroophthalmology, for example neuroprotection. Transforming growth factor-β (TGF-β) molecule, its inhibitors and antagonists have been increasingly researched as possible new anti-glaucoma drugs for its many, pleiotropic, effects. Among those effects, enhancing fibrosis is one of the most apparent, but certain members of this cytokine’s superfamily act as anti-fibrotics. Recent scientific efforts strongly support pushing back the frontier of conventional medical treatment. Current medical approaches already use effects on blood flow and neuronal quiescence, with significant systemic side-effects. Endeavours on the ophthalmologic exploitation of selected, favourable effects of pleiotropic TGF-βs could promote TGF-β, its inhibitors or specific antibodies as new, ideal drugs in glaucoma therapy.

KEY WORDS

Endothelium; Neuroprotection; Ocular Blood Flow; Transforming Growth Factor – β; Vascular Theory on Glaucoma

©2012, Medical Hypothesis, Discovery & Innovation [MEHDI] Ophthalmology Journal. All rights reserved.

INTRODUCTION

Glaucoma, a progressive optic neuropathy [1,2], is the second leading cause of vision loss. The vascular theory of glaucoma considers optic neuropathy as a consequence of blood supply that is jeopardised by a reduced ocular blood flow [3,4]. Ocular blood flow is an extremely complex process, as metabolic needs follow changes in visual function [5-10].

In vitro studies have suggested that transforming growth factor-β [TGF-β] signalling pathways regulate angiogenesis [11,12]. This originates from ALK-1 [13] and -5. Both act through receptor-regulated SMADs, though via different methods [14]. Mostly, SMADs are bone morphogenetic protein [BMP]-dependent, and are activated in various animal tissues [15]. In pulmonary or hepatic fibrosis, systemic sclerosis, glomerulosclerosis or in dermal scarring, there is noticeable evidence that TGF-β mediates a pathological increase in extracellular matrix deposition [16-20]. Although not all members of this superfamily act as pro-fibrotics [12,15,16,20], TGF-β was found to increase extracellular matrix proteins in the optic nerve [21], and affect rabbit sub-conjunctival fibroblasts [22].

Endothelium

BMPs play an important role in endothelial cell [EC] function [23-26]. Interestingly, different ECs are differently susceptible to different isoforms of TGF-β. BMP-4 and -6 [members of the TGF-β superfamily] promote EC migration and proliferation...
[27], while BMP-9 is a circulating vascular quiescence factor [28]. Vascular endothelium releases different vasoactive factors that regulate the microcirculation [29,30]. Previously, BMP-2, -4, and -7 have been reported to bind ALK1 receptors and EC, which are targets for certain ligands of the BMP members of the TGF family [23]. Vascular endothelial dysfunction is a frequent basis of many diseases [31,32]. Dysfunction in the endothelium can influence the vessel’s diameter and resistance.

Reduced levels of nitric oxide [NO] can result in decreased vasodilatation and increased vasoconstriction [33-35] connected consecutively by a decrease in nitrosylation [36] and fragmentation of DNA, all of which lead to apoptosis [37]. Low levels of nitric oxide reduce blood flow as in glaucoma. Compromised availability of NO as well as an imbalance between NO and endothelin-1 [ET-1] have been reported in glaucoma patients [38]. Patients with normal-tension glaucoma have increased plasma, and those with open angle glaucoma have aqueous humor levels of ET-1 [39,40]. Vasoconstriction inevitably leads to hypoxia, which makes it reasonable to suppose that various cytokines may be up-regulated in glaucoma [41,42].

Ocular Blood Flow

Researchers have long reported that patients with open-angle glaucoma exert altered blood flow in retinal, choroid, and retro-bulbar circulation [5-9,43]. An alteration in the eye blood supply can be further correlated to vascular endothelial dysfunction [31,32]. The narrowing of blood vessels increases resistance to flow distally, which leads to hypoxia. Several population-based studies documented retinal vascular narrowing. Structural changes might increase flow resistance, or might result in functional dysregulation of the vascular width. Reduction in the blood flow is not only limited to the eye but to the orbit and even the periphery. In some patients, blood flow reduction precedes glaucoma [44]. Intraocular pressure [IOP] alone is unlikely to cause the disruption of ocular blood flow more distinctly in normal-tension patients than high-tension ones. Reduced perfusion pressure could result in increased IOP or decreased blood pressure [44-46], and the increased viscosity of blood can be a result of a blood dyscrasia.

Neuroprotection of TGF-β

Due to its pleiotropy, the beneficial effect of TGF-β on vascular integrity has been easy to understand. That effect is not impossible to link to its many different functions, like local neuroprotective humoral agents or mediator in embryogenesis. The objective is to connect its vascular quiescence to the established endothelial NO production in order to influence cerebral perfusion [48]. Furthermore, TGF-β as the vascular-integrity guard ensures the preservation of the vessel wall, thus eliminating factors required for scarring. TGF-β mRNA is elevated for at least a week after a stroke and clearly exerts a neuroprotective role [48]. Nevertheless, in order to exploit the therapeutic properties of TGF-β, any additional roles in the brain after stroke should be clearly understood. However, the acute abolishment of blood supply, as in strokes, should not be compared to long-lasting, chronic diseases, like glaucoma. Moreover, not all TGF-β members exhibit pro-fibrotic actions.

Thanks to the neuroprotective effects of TGF-β [47-49], it is considered a future important target for therapy following a stroke. The precise function of increased TGF-β after stroke is unknown and due to its pleiotropic nature, it might well modulate NO production by ECs, orchestrate glial scarring, or function as a significant immune system regulator. Even NO is potentially neurotoxic, due to the reaction with superoxide anions, which produce reactive free radical species.

HYPOTHESIS

The ideal anti-glaucoma drug would prevent cell death of the retina with no adverse effects. However, a more realistic ideal drug would be one that reduces IOP, and reaches the retina in appropriate amounts to reduce retinal cell death, even if applied topically [2,45,50]. A variety of agents may act on growth factors, including TGF-β. Employing antibodies against the TGF-β superfamily members that are involved in angiogenesis and vessel quiescence as a treatment option for glaucoma is not new. One of the theoretical advantages of the human TGF-β2 antibody [which is the predominant form in the aqueous] is that it only acts if there is TGF-β2 in the wound, unlike an anti-metabolite [51]. Even if all of the above is neglected, the vasoconstrictive effect of ET-1, mediated by TGF-β-stimulated ALK-5 remains an open option. The employment of inhibitors of TGF-β in glaucoma therapy is also not new. N-[3, 4’-dimethoxyxynamoyl]anthranilic acid inhibits TGF-β activity and has anti-scarring effects in the body and the eye [52]. Interferon-α, an anti-fibrotic cytokine, has been shown to reduce the scarring activity of fibroblasts, although a clinical trial did not show it to be significantly better than current anti-metabolites [53].

With respect to vascular theory on the aetiology of glaucoma, the possible involvement of the TGF-β signalling system in the treatment approach of glaucoma is hypothesised, regarding endothelial dysfunction, ocular blood flow and neuroprotective features of TGF-β. This should be based on the inhibition of the pathological accumulation of the extracellular matrix and the modulation of fibrotic mechanisms with new anti-fibrotic agents. Further confirmation is needed to elucidate whether the cross-talk of TGF-β with other pathway systems already employed in the therapy of glaucoma exists. Also, it is
important to fully understand any possible impact of any TGF-β superfamily members on complex pathophysiological mechanisms in glaucoma.

DISCUSSION

The vascular theory suggests that insufficient blood supply results in glaucoma. Conditions such as normal-tension glaucoma are among the chief strongholds to this theory. The reduction of ocular blood flow often precedes glaucomatous damage. Other parts of the body in glaucoma patients might also exert reduced blood flow, e.g. the extremities. Additionally, there is an increased prevalence of ischaemic lesions in other organs of the body that result in hearing problems, heart attacks, and small strokes in these patients.

Vascular dysregulation in arteriosclerosis leads to low perfusion. Glaucoma is only faintly related to arteriosclerosis. The relationship between treatment with antihypertensive medication in glaucoma-free subjects and structural changes in the optic disc was established by epidemiologic cross-sectional studies [44,54]. Increased IOP is, to some extent, associated with high blood pressure, but glaucoma is linked to low blood pressure [44]. Finally, patients with a decrease in blood pressure while sleeping may have a higher risk of glaucoma progression. Low perfusion pressure is compensated by auto-regulation, ensuring normal perfusion. There are indications that this auto-regulation is altered in some patients with glaucoma.

Vascular conditions, such as Raynaud’s disease, apnoea during sleep [55], and migraine headaches, are all associated with glaucoma. Raynaud’s disease may be an indicator for normal-tension glaucoma. Sleep apnoea is not necessarily a vascular condition, although decreased breathing means diminutions in the intake of oxygen. Migraine headaches may indicate decreased blood flow to areas of the brain. Atrial fibrillation, possibly causing irregular flow states, is also associated. Loss of blood, haemorrhage, or the necessity for a blood transfusion, can also cause glaucomatous defects in the optic nerve and visual field [56,57].

It is almost certain that obesity would be risk factor for both increased IOP and for arteriosclerosis. High cholesterol is also a risk factor for increased IOP, but not for normal-tension glaucoma. Normal-tension glaucoma patients tend to have a lower body mass index [58], and smoking and diabetes are associated with increased IOP but not with glaucoma. Men tend to have more, and earlier, arteriosclerotic plaques, but women are actually at a higher risk for normal-tension glaucoma [59,60].

Indirect signs of altered blood flow in the eye include changes in conjunctival capillaries. Something less evident, however, is local vasoconstriction in the retina. An increased frequency of optic disc haemorrhages and gliosis-like alterations are indicators for altered blood flow. Disc haemorrhages occur in all stages of the disease and are more frequent in normal-tension glaucoma [61].

Since the heart cycle significantly reflects the arterial blood flow to the eye, the volume of all ocular sheets [especially of the choroid] and the IOP are highest during systole [62]. A connection of vasculature and glaucoma should be sought in a decrease of blood flow [5,9,31,32,43]. Decreased blood influx to the optic nerve might be either due to decreased blood pressure, narrowing of the vessels or due to increased IOP [41,44]. Decreased circulation follows decreased blood flow or decreased perfusion, which could result in increased optic nerve damage that is comparable to ischaemia of the heart or brain [30,41].

Medications could be used to lower IOP. Several different classes of medications are used in glaucoma management [63,64]. None of these is unfettered with both local and systemic side-effects. If they occur, the patient must be willing either to tolerate these, or to communicate with the treating physician to improve the drug regimen. Poor compliance with treatment regimes and follow-up visits is a major reason for disease progression to blindness in glaucoma patients. Patient education and communication must be the target of any successful therapy.

Various cytokines are released as a response to tissue injury [65], i.e. a breakdown in the blood—aqueous barrier [66], which may not be clinically visible. This feature was established for numerous agents active on a cellular level, including cytokines and growth factors. Because of their significance, tissue scarring, inhibition or antagonism of this action was the focus of glaucoma therapy.

Therefore, in the therapy of glaucoma, fibrinolytic agents have had their place [67] as they may lower IOP, however, a risk of further extra- and intraocular haemorrhage should not be neglected [68]. Fibroblast activation has also been a target of anti-glaucoma therapy [69].

However, considering all of these molecules, they may have a longer-term stimulatory effect on wound healing when breaking down. The prevention of clotting may be a more promising avenue.

Gingko biloba extract is one of the supplements that has been given to patients most frequently [70,71], and may increase peripheral blood flow [72]. A diet high in antioxidants has been believed to reduce the risk of glaucoma [73]. However, none of
the supplements have been proven in randomised controlled trials.

It is possible that, irrespective of IOP, various strains can damage the connective tissue of the optic nerve and axons. Reduced ocular blood flow, perhaps adhered by underlying vascular disease, is directly involved in the pathophysiology of glaucoma. Dysregulation or an inadequate vasomotor activity in some glaucoma patients is often combined with widening vessels in neighbouring tissues. This decreases the adjusting capacity for the different flow states in decreasing blood flow to the nerve, and thereby causes the subsequent progression of the glaucoma.

Certain carbonic anhydrase inhibitors have been shown to possibly increase ocular perfusion and produce a short-term improvement in the visual field [56,63]. The potential neuroprotective effects of various topical and systemic medications are also being investigated. In this way, the role of TGF-β, its inhibition or deleting its effect by coupling with polyclonal antibodies, needs to be viewed and evaluated as a possible ideal drug for glaucoma therapy.

CONCLUSIONS

There is a need to improve the technology for the measurement of ocular blood flow, since studies are still at the stage of simply lowering IOP [45]. Next, a requirement exists for establishing data by comparing glaucoma patients to normal individuals and to identify subgroups of those with glaucoma. After setting out all of the parameters, it will be possible to correlate these findings with optic nerve and visual field damage. That might, perhaps target vascular dysregulation to treat glaucoma patients. At present, no medication exists to increase ocular perfusion.

Neuroprotection is appreciated for the very absence of the need to treat the cause of the disease. Neuroprotective medications are, however, still being explored, and could provide protection to such neurons that continue to remain at risk. Neuroprotection attempts to address the common way of an insult, regardless of its cause.

The neuroprotective role of α2-adrenergic receptor agonists in the retina seems to be gaining importance in the treatment of glaucoma. However, the exact mechanism [supposedly transactivation] by which an α2-adrenergic agonist exhibits neuroprotection of neuronal elements in the retina still remains to be proven [74].

Endothelial integrity, blood flow, and glaucoma are active and dynamic fields that will, in the future, give adequate attention, interest, and scientific research, produce results that will help treat and withhold the progression of glaucoma.

DISCLOSURE

The authors report no conflicts of interest in this work.

REFERENCES

1. Infeld DA, O’Shea JG. Glaucoma: diagnosis and management. Postgrad Med J. 1998 Dec;74(878):709-15. PMID: 10320884.
2. Lee DA, Higginbotham EJ. Glaucoma and its treatment: a review. Am J Health Syst Pharm. 2005 Apr 1;62(7):691-9. PMID: 15790795.
3. Flammer J. The vascular concept of glaucoma. Surv Ophthalmol. 1994 May;38 Suppl:S3-6. PMID: 7940146.
4. Chung HS, Harris A, Evans DW, Kagemann L, Garzozi HJ, Martin B. Vascular aspects in the pathophysiology of glaucomatous optic neuropathy. Surv Ophthalmol. 1999 Jun;43 Suppl 1:S53-5. PMID: 10416746.
5. Harris A, Chung HS, Ciulla TA, Kagemann L. Progress in measurement of ocular blood flow and relevance to our understanding of glaucoma and age-related macular degeneration. Prog Retin Eye Res. 1999 Sep;18(5):669-87. PMID: 10438154.
6. Resch H, Karl K, Weigert G, Wolzt M, Hommer A, Schmetterer L, Garhöfer G. Effect of dual endothelin receptor blockade on ocular blood flow in patients with glaucoma and healthy subjects. Invest Ophthalmol Vis Sci. 2009 Jan;50(1):358-63. PMID: 18719081.
7. Flammer J, Orgül S, Costa VP, Orzalesi N, Kriegstein GK, Serra LM, Renard JP, Stefánsson E. The impact of ocular blood flow in glaucoma. Prog Retin Eye Res. 2002 Jul;21(4):359-93. PMID: 12150988.
8. Emre M, Orgül S, Gugleta K, Flammer J. Ocular blood flow alteration in glaucoma is related to systemic vascular dysregulation. Br J Ophthalmol. 2004 May;88(5):662-6. PMID: 15090420.
9. Grieshaber MC, Flammer J. Blood flow in glaucoma. Curr Opin Ophthalmol. 2005 Apr;16(2):79-83. PMID: 15744136.
10. Yu DY, Su EN, Cringle SJ, Yu PK. Isolated preparations of ocular vasculature and their applications in ophthalmic research. Prog Retin Eye Res. 2003 Mar;22(2):133-69. PMID: 12604056.
11. Orlova VV, Liu Z, Goumans MJ, ten Dijke P. Controlling angiogenesis by two unique TGF-β type I receptor signaling pathways. Histol Histopathol. 2011 Sep;26(9):1219-30. PMID: 21751154.
12. Pardali E, Goumans MJ, ten Dijke P. Signaling by members of the TGF-beta family in vascular morphogenesis and disease. Trends Cell Biol. 2010 Sep;20(9):556-67. PMID: 20656490.
13. Oh SP, Seki T, Goss KA, Imamura T, Yi Y, Donahoe PK, Li L, Miyazono K, ten Dijke P, Kim S, Li E. Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis. Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2626-31. PMID: 10716993.
14. Wrana JL. Crosslinking. Sci STKE. 2000 Mar 14;2000(23):re1. PMID: 11752591.
15. Mehra A, Wrana JL. TGF-beta and the Smad signal transduction pathway. Biochem Cell Biol. 2002;80(5):605-22. PMID: 12440701.
16. Verrecchia F, Mauviel A, Farge D. Transforming growth factor-beta signaling through the Smad proteins: role in systemic sclerosis. Autoimmun Rev. 2006 Oct;5(8):563-9. PMID: 17027893.

17. Panu J, Trojanowska M. Recent advances in fibroblast signaling and biology in sclerodermia. Curr Opin Rheumatol. 2004 Nov;16(6):739-45. PMID: 15577613.

18. Ihn H. Autocrine TGF-beta signaling in the pathogenesis of systemic sclerosis. J Dermatol Sci. 2008 Feb;49(2):103-13. PMID: 17628443.

19. Bonniaud P, Margetts PJ, Kolb M, Schroeder JA, Kapoun AM, Damm D, Murphy A, Chakravarty S, Dugar S, Higgins L, Putter AA, Gauldie J. Progressive transforming growth factor beta1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor. Am J Respir Crit Care Med. 2005 Apr 15;171(8):889-98. PMID: 15563636.

20. Wells RG. Fibrogenesis. V. TGF-beta signaling pathways. Am J Physiol Gastrointest Liver Physiol. 2000 Nov;279(5):G845-50. PMID: 11052979.

21. Zode GS, Sethi A, Brun-Zinkernagel AM, Chang IF, Clark AF, Wordinger RJ. Transforming growth factor-beta increases extracellular matrix proteins in optic nerve head cells via activation of the SMAD signaling pathway. Mol Vis. 2011;17:1745-58.

22. Jung SA, Lee HK, Yoon JS, Kim SJ, Kim CY, Song H, Hwang KC, Lee JB, Lee JH. Upregulation of TGF-beta-induced tissue transglutaminase expression by PI3K-Akt pathway activation in human subconjunctival fibroblasts. Invest Ophthalmol Vis Sci. 2007 May;48(5):1952-8. PMID: 17460246.

23. David L, Mallet C, Mazerbourg S, Feige JJ, Bailly S. Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood. 2007 Mar 1;109(5):1953-61. PMID: 17068149.

24. Huylebroeck D. Bone morphogenetic proteins go endothelial. Blood. 2007 mar; 109(5):1794-1795.

25. Gangopahayy A, Oran M, Bauer EM, Wertz JW, Comhair SA, Erzurum SC, Bauer PM. Bone morphogenetic protein receptor II is a novel mediator of endothelial nitric oxide synthase activation. J Biol Chem. 2011 Sep 23;286(38):33134-40. PMID: 21808054.

26. Ricard N, Ciais D, Levet S, Subileau M, Mallet C, Zimmer TA, Lee SJ, Bidart M, Feige JJ, Bailly S. BMP9 and BMP10 are critical for postnatal retinal vascular remodeling. Blood. 2012 Jun 21;119(25):6162-71. PMID: 22566602.

27. Tian XY, Yung LH, Wong WT, Liu J, Leung FP, Liu L, Chen Y, Kong SK, Kwan KM, Ng SM, Lai PB, Yung LM, Yao X, Huang Y. Bone morphogenetic protein-4 induces endothelial cell apoptosis through oxidative stress-dependent p38MAPK and JNK pathway. J Mol Cell Cardiol. 2012 Jan;52(1):237-44. PMID: 22064324.

28. David L, Mallet C, Keramidas M, Lamande N, Gasc JM, Dupuis-Girod S, Plauchu H, Feige JJ, Bailly S. Bone morphogenetic protein-9 is a circulating vascular quiescence factor. Circ Res. 2008 Apr 25;102(8):914-22. PMID: 18309101.

29. Orgül S, Prünte C, Flammer J. Endothelium-derived vasoactive substances relevant to normal-tension glaucoma. Curr Opin Ophthalmol. 1998 Apr;9(2):88-94. PMID: 10180520.

30. Prünte C, Orgül S, Flammer J. Abnormalities of microcirculation in glaucoma: facts and hints. Curr Opin Ophthalmol. 1998 Apr;9(2):50-5. PMID: 10180514.

31. Nadar S, Blann AD, Lip GY. Endothelial dysfunction: methods of assessment and application to hypertension. Curr Pharm Des. 2004;10(29):3591-605. PMID: 15579056.

32. Drexler H, Hornig B. Endothelial dysfunction in human disease. J Mol Cell Cardiol. 1999 Jan;31(1):51-60. PMID: 10072715.

33. Neufeld AH, Sawada A, Becker B. Inhibition of nitric-oxide synthase 2 by aminoguanidine provides neuroprotection of retinal ganglion cells in a rat model of chronic glaucoma. Proc Natl Acad Sci U S A. 1999 Aug 17;96(17):9944-8. PMID: 10449799.

34. Neufeld AH. Nitric oxide: a potential mediator of retinal ganglion cell damage in glaucoma. Surv Ophthalmol. 1999 Jun;43 Suppl 1:S129-35. PMID: 10416755.

35. Morgan J, Caprioli J, Kosey K. Nitric oxide mediates excitotoxic and apoptotic damage in rat retinal ganglion cells cocultured with astroglia. Arch Ophthalmol. 1999 Nov;117(11):1524-9. PMID: 10565522.

36. Tang CH, Wei W, Liu L. Regulation of DNA repair by S-nitrosylation. Biochim Biophys Acta. 2012 Jun;1820(6):730-5. PMID: 21571039.

37. Taylor EL, Megson IL, Haslett C, Rossi AG. Dissociation of DNA fragmentation from other hallmarks of apoptosis in nitric oxide-treated neutrophils: differences between individual nitric oxide donor drugs. Biochem Biophys Res Commun. 2001 Dec 21;289(5):1229-36. PMID: 11741325.

38. Chang CJ, Chiang CH, Chow JC, Lu DW. Aqueous humor nitric oxide levels differ in patients with different types of glaucoma. J Ocul Pharmacol Ther. 2000 Oct;16(5):399-406. PMID: 11110031.

39. Tezel G, Kass MA, Kolker AE, Becker B, Wax MB. Plasma and aqueous humor endothelin levels in primary open-angle glaucoma. J Glaucoma. 1997 Apr;6(2):83-9. PMID: 9098815.

40. Resch H, Garhofer G, Fuchsberger-Mayrl G, Hommer A, Schmetterer L. Endothelial dysfunction in glaucoma. Acta Ophthalmol. 2009 Feb;87(1):4-12. PMID: 18507728.

41. Stefánsson E, Pedersen DB, Jensen PK, la Cour M, Kiilgaard JF, Bang K, Eyseleinsson T. Optic nerve oxygenation. Prog Retin Eye Res. 2005 May;24(3):307-312. PMID: 15708831.

42. Gass A, Flammer J, Linder L, Romerio SC, Gasser P, Haefeli WE. Inverse correlation between endothelin-1-induced peripheral microvascular vasconstriction and blood pressure in glaucoma patients. Graefes Arch Clin Exp Ophthalmol. 1997 Oct;235(10):634-8. PMID: 9349947.

43. Wilensky JT. The role of diurnal pressure measurements in the management of open angle glaucoma. Curr Opin Ophthalmol. 2004 Apr;15(2):90-2. PMID: 15021217.

44. Caprioli J, Coleman AL; Blood Flow in Glaucoma. Ophthalmology. 2010 May;117(9):1641-51. PMID: 20399924.

45. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M; Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure...
and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002 Oct;120(10):1268-79. PMID: 12365904.

46. Shields MB. Normal-tension glaucoma: is it different from primary open-angle glaucoma? Curr Opin Ophthalmol. 2008 Mar;19(2):85-8. PMID: 18301279.

47. Doyle KP, Cekanaviciute E, Mamer LE, Buckwalter MS. TGFβ signaling in the brain increases with aging and signals to astrocytes and innate immune cells in the weeks after stroke. J Neuroinflammation. 2010 Oct 11;7:62. PMID: 20937129.

48. Kaushik S, Pandav SS, Ram J. Neuroprotection in glaucoma. J Postgrad Med. 2003 Jan-Mar;49(1):90-5. PMID: 12865582.

49. García-Campos J, Villena A, Díaz F, Vidal L, Moreno M, Pérez de Vargas I. Morphological and functional changes in experimental ocular hypertension and role of neuroprotective drugs. Histol Histopathol. 2007 Dec;22(12):1399-411. PMID: 17701920.

50. Grieshaber MC, Flammer J. Is the medication used to achieve the target intraocular pressure in glaucoma therapy of relevance?--an exemplary analysis on the basis of two beta-blockers. Prog Retin Eye Res. 2010 Jan;29(1):79-93. PMID: 19733652.

51. Tripathi RC, Li J, Chan WF, Tripathi BL. Aqueous humor in glaucomatous eyes contains an increased level of TGF-beta 2. Exp Eye Res. 1994 Dec;59(6):723-7. PMID: 7698265.

52. Ito S, Sakamoto T, Tahara Y, Goto Y, Akazawa K, Ishibashi T, Inomata H. The effect of tranilast on experimental proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol. 1999 Aug;237(8):691-9. PMID: 10459620.

53. Zimmermann TJ, Leader B, Kaufman HE. Advances in ocular pharmacology. Annu Rev Pharmacol Toxicol. 1980;20:415-28. PMID: 6155823.

54. Bhargava M, Ikram MK, Wong TY. How does hypertension affect your eyes? J Hum Hypertens. 2012 Feb;26(2):71-83. PMID: 21509040.

55. Faridi O, Park SC, Liebmann JM, Ritch R. Glaucoma and obstructive sleep apnoea syndrome. Clin Experiment Ophthalmol. 2012 May-Jun;40(4):408-19. PMID: 22339177.

56. Schor KS, De Moraes CG, Teng CC, Tello C, Liebmann JM, Ritch R. Rates of visual field progression in distinct optic disc phenotypes. Clin Experiment Ophthalmol. 2012 Sep-Oct;40(7):706-12. PMID: 22429789.

57. Krudy JS. Effect of transusions of stored blood and blood-substitutes in the intraocular tension. Pol Med J. 1966;5(5):1124-31. PMID: 5958800.

58. Gasser P, Stümpfig D, Schötzau A, Ackermann-Liebrich U, Flammer J. Body mass index in glaucoma. J Glaucoma. 1999 Feb;8(1):8-11. PMID: 10084268.

59. Coleman AL, Kodjebachev G. Risk factors for glaucoma needing more attention. Open Ophthalmol J. 2009 Sep 17;3:38-42. PMID: 19816585.

60. Renard JP, Rouland JF, Bron A, Sellerm E, Nordmann JP, Baudouin C, Denis P, Villain M, Chaine G, Colin J, de Pouvoirville G, Pinchinat S, Moore N, Estephan M, Delcourt C. Nutritional, lifestyle and environmental factors in ocular hypertension and primary open-angle glaucoma: an exploratory case-control study. Acta Ophthalmol. 2012 Mar 6. [Epub ahead of print] PMID: 22394398.

61. Orgül S, Flammer J. Optic-disc hemorrhages: Cause or result of ischemia?. Neuro-ophthalmology. 1994;14(2):97–101.

62. Singh K, Dion C, Costantino S, Wajszilber M, Lesk MR, Ozaki T. Development of a novel instrument to measure the pulsatile movement of ocular tissues. Exp Eye Res. 2010 Jul;91(1):63-8. PMID: 20398654.

63. Lee AJ, Goldberg I. Emerging drugs for ocular hypertension. Expert Opin Emerg Drugs. 2011 Mar;16(1):137-61. PMID: 21352074.

64. Marquis RE, Whitson JT. Management of glaucoma: focus on pharmacological therapy. Drugs Aging. 2005;22(1-2):1-21. PMID: 15663346.

65. Hopkins SJ. The pathophysiological role of cytokines. Leg Med (Tokyo). 2003 Mar;5 Suppl 1:545-57. PMID: 12935551.

66. Hauriot V, Villacampa P, Ribera A, Llombart C, Bosch A, Nacher V, Ramos D, Ayuso E, Segovia JC, Bueran JA, Ruberte J, Bosch F. Increased intraocular insulin-like growth factor-I triggers blood-retinal barrier breakdown. J Biol Chem. 2009 Aug 21;284(34):22961-9. PMID: 19473988.

67. Zalta AH, Sweeney CP, Zalta AK, Kaufman AH. Intracamerale tissue plasminogen activator use in a large series of eyes with valved glaucoma drainage implants. Arch Ophthalmol. 2002 Nov;120(11):1487-93. PMID: 12427061.

68. Azuara-Blanco A, Wilson RP. Intraocular and extraocular bleeding after intracameral injection of tissue plasminogen activator. Br J Ophthalmol. 1998 Nov;82(11):1345-6. PMID: 9924355.

69. Khaw PT, Octleston NL, Schultz G, Grierson I, Sherwood MB, Larkin G. Activation and suppression of fibroblast function. Eye (Lond). 1994;8(2):188-95. PMID: 7958020.

70. Cybulska-Heinrich AK, Mozaffarieh M, Flammer J. Ginkgo biloba: an adjuvant therapy for progressive normal and high tension glaucoma. Mol Vis. 2012;18:390-402. PMID: 22355250.

71. Parikh RS, Parikh SR. Alternative therapy in glaucoma management: is there any role? Indian J Ophthalmol. 2011 Jan;59 Suppl:S158-60. PMID: 21150028.

72. Park JW, Kwon HJ, Chung WS, Kim CY, Seong GJ. Short-term effects of Ginkgo biloba extract on peripapillary retinal blood flow in normal tension glaucoma. Korean J Ophthalmol. 2011 Oct;25(5):323-8. PMID: 21976939.

73. Lugasi A, Horvahovich P, Dworschák E. Additional information to the in vitro antioxidant activity of Ginkgo biloba L. Phytother Res. 1999 Mar;13(2):160-2. PMID: 10130193.

74. Arthur S, Cantor LB. Update on the role of alpha-agonists in glaucoma management. Exp Eye Res. 2011 Sep;93(3):271-83. PMID: 21524649.